Skip To Main Content
Barbara Galbardi on Muck Rack

Barbara Galbardi

As seen in: Nature, JAMA (The Journal of the American Medical Association), BioRxiv, European Journal of Cancer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barbara

Contact Barbara, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Pan-cancer multi-omic integration of Trop2 reveals biological determinants and translational implications for ADC therapy

|
By Giulia Notini, Barbara Galbardi, Giulia Viale, Matteo M. Naldini, Carlo Bosi, Giacomo De Micheli, Luca Licata, Marco Mariani, Marta Piras, Carmen Criscitiello, Marco Barreca, Maurizio Callari, Caterina Zanibelli, Francesca Patanè, Antonella Chiavassa, Jose Perez-Garcia, H. Ali, Javier Cortés, Lajos Pusztai, Luca Gianni, Giampaolo Bianchini, Matteo Dugo
| Nature Verified
Abstract Trop2–directed antibody-drug conjugates (ADCs) show activity across epithelial cancers, yet determinants of target expression in tumors and normal tissues remain poorly defined. We integrated bulk and single-cell transcriptomic profiles from over 20,000 samples across TCGA, GTEx and public atlases to map TACSTD2 expression, regulation and functional correlates in solid malignancies and healthy epithelia.
Open in Who Shared Issue with article?

Completion Rate and Positive Results Reporting Among Immunotherapy Trials in Breast Cancer, 2004-2023

|
By Marco Mariani, Giulia Viale, Barbara Galbardi, Luca Licata
| JAMA (The Journal of the American Medical Association) Verified
Key Points Question What fraction of immunotherapy trials launched since 2004 have reported an outcome and translated into positive phase III randomized trials, and what features are associated with failure to report results?
Open in Who Shared Issue with article?

Development and validation of a gene expression score to account for tumour purity and improve prognostication in breast cancer

|
By Matteo Dugo, Barbara Galbardi, Marco Barreca, Balazs Gyorrfy
| BioRxiv
Abstract The prevalence of malignant cells in clinical specimens, or tumour purity, is affected by both intrinsic biological factors and extrinsic sampling bias. Molecular characterization of large clinical cohorts is typically performed on bulk samples; data analysis and interpretation can be biased by tumour purity variability. Transcription-based strategies to estimate tumour purity have been proposed, but no breast cancer specific method is available yet.
Open in Who Shared Issue with article?
See all 4 articles